AGN 209323

Drug Profile

AGN 209323

Alternative Names: AGN-0001; AGN-001; AGN-209323; EHT-0001; EHT-001; EHT/AGN-0001

Latest Information Update: 05 Jul 2013

Price : $50

At a glance

  • Originator Allergan; ExonHit Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Analgesics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 06 Feb 2013 Bristol-Myers Squibb returns the AGN 209323 programme to Allergan and Diaxonhit
  • 06 Feb 2013 Discontinued - Phase-II for Neuropathic pain in USA (PO)
  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top